Search

Your search keyword '"Weers, Jeffry G."' showing total 137 results
Start Over Author "Weers, Jeffry G." Search Limiters Peer Reviewed
137 results on '"Weers, Jeffry G."'

25. Idealhalers Versus Realhalers: Is It Possible to Bypass Deposition in the Upper Respiratory Tract?

Author

Weers, Jeffry G., primary, Son, Yoen-Ju, additional, Glusker, Mark, additional, Haynes, Alfred, additional, Huang, Daniel, additional, Kadrichu, Nani, additional, Le, John, additional, Li, Xue, additional, Malcolmson, Richard, additional, Miller, Danforth P., additional, Tarara, Thomas E., additional, Ung, Keith, additional, and Clark, Andy, additional

Published
2019
Full Text
View/download PDF

32. In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.

Author

Weers, Jeffry G., Clark, Andrew R., Rao, Nagaraja, Ung, Keith, Haynes, Alfred, Khindri, Sanjeev K., Perry, Sheryl A., Machineni, Surendra, and Colthorpe, Paul

Subjects
*DRUG delivery devices, *COMBINATION drug therapy, *AEROSOL therapy, *PHARMACOKINETICS, *RESPIRATION
Abstract

Background: Establishing robust in vitro-in vivo correlations (IVIVC) between aerosol performance, pharmacokinetics, and clinical efficacy is critical in developing bioequivalent drug-device combination products. Recent studies have demonstrated that realistic throat models tested under realistic test conditions may provide good IVIVC with respect to total lung deposition. Methods: The Alberta idealized throat (AIT) model was utilized with mean peak inspiratory flow rates determined from patient breathing studies. Various formulations of indacaterol (e.g., lactose blends, fixed dose combinations, engineered PulmoSphere™ particles) were tested in the AIT model and in clinical pharmacokinetic studies. Results: Good IVIVC were observed with respect to total lung deposition, systemic delivery, and the contribution of oral absorption to systemic delivery, with percentage differences from the mean in vivo measurements <15%, with most comparisons <5%. Conclusions: Anatomical throat models represent an exciting tool to aid in formulation development of pharmaceutical aerosols. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

37. In Vitro Assessment of Dose Delivery Performance of Dry Powders for Inhalation.

Author

Ung, Keith T., Rao, Nagaraja, Weers, Jeffry G., Clark, Andrew R., and Chan, Hak-Kim

Subjects
DRUG delivery systems, INHALATION administration, IN vitro studies, PARTICLE size determination, PERFORMANCE evaluation, PRESSURE drop (Fluid dynamics), EMPIRICAL research
Abstract

The aerosol performance of engineered porous particles (PulmoSphere™) for inhalation as a function of powder properties (particle size and density) was assessed using an idealized replica of the adult human upper respiratory tract (URT) known as the Alberta mouth-throat model. Engineered placebo powders were prepared using the PulmoSphere™ technology, which is based on spray-drying an emulsion feedstock and produces porous particles with well-controlled size and density. These placebo powders are useful surrogates for a class of potent active formulations, and covered a range of particle sizes and densities, representing a particle design space relevant to dry powder inhalers. The Alberta idealized mouth-throat model was used forin vitromeasurement of oropharyngeal (mouth and throat) losses and to estimate the total lung dose for different inhalation drug products. Thein vitrolung doses measured with the mouth-throat model were compared to predictions of lung dose from semi-empirical numerical models of oropharyngeal deposition. Data from the mouth-throat model and numerical models were used to rank order oropharyngeal losses and flow-rate dependence in the 1–6 kPa pressure drop range. Aerosol performance of the PulmoSphere™powders was favored by low-particle density and large geometric size, with the oropharyngeal deposition and flow rate dependence being lower for powders with median particle diameter ≥2.5 microns. In comparison, data from lactose-blend formulations showed significantly higher oropharyngeal deposition and flow rate dependence. The idealized mouth-throat model provides a reasonablein vitroestimate of dose delivered to the lungs, and is a useful tool for studying the effect of factors such as drug/device and inhalation airflow. Copyright 2014 American Association for Aerosol Research [ABSTRACT FROM PUBLISHER]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results